Baader Bank Remains a Buy on K+S Aktiengesellschaft (0Q2N)
Baader Bank analyst Konstantin Wiechert maintained a Buy rating on K+S Aktiengesellschaft (0Q2N – Research Report) on May 7 and set a price target of €16.00. The company's shares closed yesterday at €15.57.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Wiechert is a 4-star analyst with an average return of 5.0% and a 64.71% success rate.
In addition to Baader Bank, K+S Aktiengesellschaft also received a Buy from Kepler Capital 's Christian Faitz in a report issued on April 29. However, on April 30, DZ BANK AG maintained a Hold rating on K+S Aktiengesellschaft (LSE: 0Q2N).
Based on K+S Aktiengesellschaft's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €925.1 million and a GAAP net loss of €53 million. In comparison, last year the company earned a revenue of €974 million and had a net profit of €39.7 million
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Safety Shot, Inc. and Yerbaé Brands Corp Majority Shareholders Approve Proposed Acquisition of Yerbaé Brands Corp.
SCOTTSDALE, AZ, June 13, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) ('Safety Shot' or the 'Company'), a wellness and dietary supplement company, today announced that it a majority of its shareholders have voted by a majority to approve the proposed acquisition of Yerbaé Brands Corp. (TSX-V: YERB.U) ('Yerbaé'), a plant-based functional beverage company. The approval was obtained at Safety Shot's Special Meeting of Stockholders held earlier yesterday. Following the completion of the merger, which is expected to occur next week, the combined company will continue to operate under the name Safety Shot, Inc., and its common stock will continue to trade on The Nasdaq Capital Market under the ticker symbol 'SHOT'. Upon closing, Yerbaé's shares will be delisted from the TSX Venture Exchange. Jarrett Boon, Chief Executive Officer of Safety Shot, stated, 'On behalf of Safety Shot's Board of Directors, I want to extend our sincere gratitude to our stockholders for their overwhelming support and majority approval of this transformative acquisition. This vote marks a pivotal milestone and is a testament to the significant strategic value and growth potential that the combination of Safety Shot and Yerbaé represents. We are thrilled to move forward with satisfying the final closing conditions and look forward to welcoming the Yerbaé team and completing the transaction next week.' As previously announced on January 8, 2025, the acquisition brings together Safety Shot's innovative wellness solutions, including its patented Sure Shot™ rapid alcohol reducer product, with Yerbaé's popular and growing line of plant-based, zero-sugar, zero-calorie energy beverages. The combination is expected to create a powerful force in the functional beverage market by leveraging Yerbaé's robust retail and distribution network to accelerate the growth of both brands. The Company will announce further details upon the formal completion of the final voting results from the Special Meeting of Stockholders will be made available in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission. Advisors Maxim Group LLC is serving as the exclusive financial advisor to Safety Shot in connection with the transaction. About Safety Shot, Inc. Safety Shot, Inc., a wellness and dietary supplement company, has developed Sure Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy, and overall mood. Sure Shot is available for purchase online at and Amazon. Safety Shot, Inc. is introducing business-to-business sales of Sure Shot to distributors, retailers, restaurants, and bars throughout 2025. About Yerbaé Brands Corp. Founded in 2017, Yerbaé Brands Corp. is a plant-based functional beverage company that has captured the attention of health-conscious consumers with its line of zero-sugar, zero-calorie energy beverages. Yerbaé's products are formulated with yerba mate and other clean ingredients to provide a 'better-for-you' energy boost. Investor Relations: Phone: 561-244-7100 Email: investors@ Forward-Looking Statements: This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding the expected completion of the acquisition. These forward-looking statements are based on the current expectations of the management of Safety Shot and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Safety Shot, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Yahoo
35 minutes ago
- Yahoo
XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market
GOTHENBURG, SWEDEN / / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA) Business Award 2025, presented at the Swedish Embassy - House of Sweden - in Washington, D.C. The SACC-USA Business Award honors companies that strengthen Swedish-American business ties through industry excellence, innovation, and cross-border impact. "To win the SACC-USA Business Award is a tremendous honor and a testament to our team's unwavering commitment to saving lives," said Christoffer Rosenblad, CEO of XVIVO. "It affirms the importance of our vision that nobody should die waiting for a new organ and reinforces our momentum as we continue to help clinicians and researchers push the boundaries of organ transplantation to serve more patients in the U.S." The award highlights the deep connection between Swedish innovation and advancements in American healthcare. Following a year of substantial growth in the U.S. market, XVIVO's success is driven by the increasing need for organ perfusion and preservation technologies that help transplant teams save more lives. "As the demand for more organs continues to grow, XVIVO is supporting the system through groundbreaking solutions rooted in science, technology, and measurable impact," said André Persson, Jury Chair, SACC USA Business Award, with SACC-USA. "Their rapid growth and transformative contributions to the U.S. healthcare system exemplify the forward-thinking innovation we celebrate with the SACC-USA Business Award." June 13, 2025GothenburgChristoffer Rosenblad, CEOXVIVO Perfusion AB (publ) For further information, please contact: Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: Nordström, CFO, +46 73 519 21 64, e-mail: About Us Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website Attachments XVIVO honored with 2025 SACC-USA Business Award for life-saving innovation and growth in the U.S. market SOURCE: XVIVO Perfusion AB View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market
GOTHENBURG, SWEDEN / / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA) Business Award 2025, presented at the Swedish Embassy - House of Sweden - in Washington, D.C. The SACC-USA Business Award honors companies that strengthen Swedish-American business ties through industry excellence, innovation, and cross-border impact. "To win the SACC-USA Business Award is a tremendous honor and a testament to our team's unwavering commitment to saving lives," said Christoffer Rosenblad, CEO of XVIVO. "It affirms the importance of our vision that nobody should die waiting for a new organ and reinforces our momentum as we continue to help clinicians and researchers push the boundaries of organ transplantation to serve more patients in the U.S." The award highlights the deep connection between Swedish innovation and advancements in American healthcare. Following a year of substantial growth in the U.S. market, XVIVO's success is driven by the increasing need for organ perfusion and preservation technologies that help transplant teams save more lives. "As the demand for more organs continues to grow, XVIVO is supporting the system through groundbreaking solutions rooted in science, technology, and measurable impact," said André Persson, Jury Chair, SACC USA Business Award, with SACC-USA. "Their rapid growth and transformative contributions to the U.S. healthcare system exemplify the forward-thinking innovation we celebrate with the SACC-USA Business Award." June 13, 2025GothenburgChristoffer Rosenblad, CEOXVIVO Perfusion AB (publ) For further information, please contact: Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: Nordström, CFO, +46 73 519 21 64, e-mail: About Us Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website Attachments XVIVO honored with 2025 SACC-USA Business Award for life-saving innovation and growth in the U.S. market SOURCE: XVIVO Perfusion AB View the original press release on ACCESS Newswire
